Under the agreement, both the parties will jointly work for identifying, characterizing and optimizing new treatments for malaria.
The ‘Orthology Malaria’ project aims at developing drug candidates from a set of Sanofi-aventis‘ compounds that have been selected for their potential activity against malaria parasites.
Each stage of the project will be investigated by the Sanofi-aventis/MMV joint steering committee and assessed according to MMV’s criteria for compound progression.
Sanofi-aventis Global Research & Development president Elias Zerhouni said this new partnership will enable them to mobilize each organization’s expertise, resources and know-how to identify novel medicines for malaria patients.